The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Patient satisfaction with subcutaneous isatuximab in myeloma: IRAKLIA and IZALCO
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses patient experience with subcutaneous isatuximab administered via an on-body injector (OBI) in multiple myeloma. Dr Cerchione highlights findings from the Phase III IRAKLIA (NCT05405166) and Phase II IZALCO (NCT05704049) trials, emphasizing patient satisfaction, convenience, and treatment preference. He also discusses the potential of OBI administration to reduce hospital visits and facilitate home-based treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
